Molecular antimicrobial susceptibility testing in sepsis.

AST ICU MDR antibiotics bacteremia microbiology molecular testing pneumonia sepsis septic shock

Journal

Future microbiology
ISSN: 1746-0921
Titre abrégé: Future Microbiol
Pays: England
ID NLM: 101278120

Informations de publication

Date de publication:
05 Jan 2024
Historique:
medline: 5 1 2024
pubmed: 5 1 2024
entrez: 5 1 2024
Statut: aheadofprint

Résumé

Rapidly detecting and identifying pathogens is crucial for appropriate antimicrobial therapy in patients with sepsis. Conventional diagnostic methods have been a great asset to medicine, though they are time consuming and labor intensive. This work will enable healthcare professionals to understand the bacterial community better and enhance their diagnostic capacity by using novel molecular methods that make obtaining quicker, more precise results possible. The authors discuss and critically assess the merits and drawbacks of molecular testing and the added value of these tests, including the shift turnaround time, the implication for clinicians' decisions, gaps in knowledge, future research directions and novel insights or innovations. The field of antimicrobial molecular testing has seen several novel insights and innovations to improve the diagnosis and management of infectious diseases. Sepsis is a life-threatening reaction to an infection. This infection is normally caused by a bacteria. Identifying the bacteria that has caused the infection is very important to choosing the best treatment. This is usually done using molecular testing. This article discusses the advantages and disadvantages of molecular testing, which tests are available and the value of these tests in clinical practice, the implication of molecular tests for clinicians' decisions and the gaps in our knowledge. It also discusses future innovations in molecular testing.

Autres résumés

Type: plain-language-summary (eng)
Sepsis is a life-threatening reaction to an infection. This infection is normally caused by a bacteria. Identifying the bacteria that has caused the infection is very important to choosing the best treatment. This is usually done using molecular testing. This article discusses the advantages and disadvantages of molecular testing, which tests are available and the value of these tests in clinical practice, the implication of molecular tests for clinicians' decisions and the gaps in our knowledge. It also discusses future innovations in molecular testing.

Identifiants

pubmed: 38180334
doi: 10.2217/fmb-2023-0128
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Ignacio Martin-Loeches (I)

Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St James' Hospital, D08 NHY1, Dublin, Ireland.
Hospital Clinic, Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Ciberes, 08036 Barcelona, Spain.

João Gonçalves Pereira (JG)

Hospital Vila Franca de Xira, Portugal.
Faculdade de Medicina da Universidade de Lisboa.

Tee Keat Teoh (TK)

Department of Clinical Microbiology, St James' Hospital, Dublin, Ireland.

Gavin Barlow (G)

York Biomedical Research Institute, University of York and Hull York Medical School, UK.
Hull University Teaching Hospitals NHS Trust, Hull, UK.

Laurent Dortet (L)

Department of Bacteriology-Hygiene, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
INSERM UMR 1184, RESIST Unit, Paris-Saclay University, Le Kremlin-Bicêtre, France.
French National Reference Center for Antimicrobial Resistance, France.

Enitan D Carrol (ED)

University of Liverpool, Institute of Infection, Veterinary and Ecological Sciences, Liverpool, UK.
Alder Hey Children's Hospital, Department of Infectious Diseases, Liverpool, UK.

Ulrike Olgemöller (U)

Department of Cardiology and Pneumology, University of Goettingen, Goettingen, Germany.

Sara E Boyd (SE)

St George's University Hospital NHS Foundation Trust, London, UK.
Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance, Imperial College London, London, UK.

Julien Textoris (J)

Medical Affairs, bioMérieux SA, Marcy l'Etoile, France.

Classifications MeSH